Combining MSI2 inhibition with TKI therapy improves drug resistance and senescence in chronic myeloid leukemia models, suggesting new treatment strategies.
In conclusion, MSI2 inhibition, in combination with TKI therapy, has shown to overcome drug resistance and mitigate senescence in preclinical CML models, and suggesting a potential strategy to target CML LSCs.
No takes yet. Share an insight, caveat, or question.
Yousaf et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: